Clinical utility of alpha-1 proteinase inhibitor in the management of adult patients with severe alpha-1 antitrypsin deficiency: a review of the current literature

被引:9
作者
Parr, David G. [1 ]
Lara, Beatriz [1 ]
机构
[1] Univ Hosp Coventry, Dept Resp Med, Cardioresp Div, Coventry, W Midlands, England
来源
DRUG DESIGN DEVELOPMENT AND THERAPY | 2017年 / 11卷
关键词
alpha-1 antitrypsin deficiency; augmentation or replacement therapy; computed tomography; emphysema; COPD; COMPUTED-TOMOGRAPHY SCANS; AUGMENTATION THERAPY; ALPHA(1)-ANTITRYPSIN DEFICIENCY; LUNG DENSITY; HEALTH-STATUS; ALPHA(1)-PROTEASE INHIBITOR; ANTITRYPSIN DEFICIENCY; BIOCHEMICAL EFFICACY; REPLACEMENT THERAPY; PULMONARY-EMPHYSEMA;
D O I
10.2147/DDDT.S105207
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alpha-1 antitrypsin (AAT) functions primarily to inhibit neutrophil elastase, and its deficiency predisposes individuals to the development of chronic obstructive pulmonary disease (COPD). The putative protective serum concentration is generally considered to be above a threshold of 11 mu M/L, and therapeutic augmentation of AAT above this value is believed to retard the progression of emphysema. Several AAT preparations, all derived from human donor plasma, have been commercialized since approval by the US Food and Drug Administration (FDA) in 1987. Biochemical efficacy has been demonstrated by augmentation of pulmonary antiprotease activity, but demonstration of clinical efficacy in randomized, placebo-controlled trials has been hampered by the practical difficulties of performing conventional studies in a rare disease with a relatively long natural history. Computed tomography has been applied to measure lung density as a more specific and sensitive surrogate outcome measure of emphysema than physiologic indices, such as forced expiratory volume in 1 second, and studies consistently show a therapeutic reduction in the rate of lung density decline. However, convincing evidence of benefit using traditional clinical measures remains elusive. Intravenous administration of AAT at a dose of 60 mg/kg/week is the commonest regime in use and has well-documented safety and tolerability. International and national guidelines on the management of AAT deficiency recommend intravenous augmentation therapy to supplement optimized usual COPD treatment in patients with severe deficiency and evidence of lung function impairment.
引用
收藏
页码:2149 / 2162
页数:14
相关论文
共 95 条
  • [2] [Anonymous], 1982, JAMA, V248, P1693
  • [3] [Anonymous], 2016, EMA5542602016
  • [4] [Anonymous], 2010, COCHRANE DATABASE SY
  • [5] Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema
    Blanco, Ignacio
    Lara, Beatriz
    De Serres, Frederick
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [6] Burnout T, 1986, VOX SANG, V52, P291
  • [7] Reduction of severe exacerbations and hospitalization-derived costs in alpha-1-antitrypsin-deficient patients treated with alpha-1-antitrypsin augmentation therapy
    Carlos Barros-Tizon, Juan
    Luisa Torres, Maria
    Blanco, Ignacio
    Teresa Martinez, Maria
    [J]. THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2012, 6 (02) : 67 - 78
  • [8] Carroll TP, ALPHA 1 ANTITRYPSIN
  • [9] Casas F, DEFICIT ALFA 1 ANTIT
  • [10] Indications for Active Case Searches and Intravenous Alpha-1 Antitrypsin Treatment for Patients With Alpha-1 Antitrypsin Deficiency Chronic Pulmonary Obstructive Disease: An Update
    Casas, Francisco
    Blanco, Ignacio
    Teresa Martinez, Maria
    Bustamante, Ana
    Miravitlles, Marc
    Cadenas, Sergio
    Hernandez, Jose M.
    Lazaro, Lourdes
    Rodriguez, Esther
    Rodriguez-Frias, Francisco
    Torres, Maria
    Lara, Beatriz
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2015, 51 (04): : 185 - 192